Manon A A Jansen
Overview
Explore the profile of Manon A A Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Extending the IMQ Model: Deep Characterization of the Human TLR7 Response for Early Drug Development
van den Noort J, Assil S, Ronner M, Osse M, Pot I, Yavuz Y, et al.
Inflammation
. 2024 Aug;
PMID: 39183259
Imiquimod (IMQ; brand name Aldara®) is a registered topical agent that has been proven to induce local inflammation via the Toll-like receptor (TLR)7 pathway. The purpose of this study was...
2.
Ten Voorde W, Wind S, Abdisalaam I, Mancini A, Linders F, Jansen M, et al.
Eur J Pharm Sci
. 2024 Jul;
204:106867.
PMID: 39084539
Non-healing wounds represent a substantial medical burden with few effective treatments available. To address this challenge, we developed a novel epidermal wound healing model using suction blisters in healthy volunteers....
3.
Eveleens Maarse B, Ronner M, Jansen M, Niemeyer-van der Kolk T, In t Veld A, Klaassen E, et al.
Immunol Res
. 2024 May;
72(4):776-787.
PMID: 38748319
The gut microbiome can modulate systemic inflammation and is therefore target for immunomodulation. Immunomodulating effects of EDP1815, a bacterial commensal strain of Prevotella histicola, were studied in healthy participants. Effects...
4.
Jodl S, Ten Voorde W, Klein S, Wagenfeld A, Zollmann F, Feldmuller M, et al.
Clin Transl Sci
. 2024 Mar;
17(3):e13771.
PMID: 38511583
This study evaluated and characterized the pharmacological activity of the orally administered interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors BAY1834845 (zabedosertib) and BAY1830839 in healthy male volunteers. Participants received one of...
5.
Assil S, Buters T, Hameeteman P, Hallard C, Treijtel N, Niemeyer-van der Kolk T, et al.
Front Immunol
. 2023 Aug;
14:1197650.
PMID: 37545524
Imiquimod (IMQ) is a topical agent that induces local inflammation the Toll-like receptor 7 pathway. Recently, an IMQ-driven skin inflammation model was developed in healthy volunteers for proof-of-pharmacology trials. The...
6.
In t Veld A, Jansen M, de Kam M, Yavuz Y, Moes D, Oudhoff K, et al.
Pharmaceutics
. 2023 Jun;
15(6).
PMID: 37376083
Mycophenolate mofetil (MMF) is part of the standard immunosuppressive treatment after transplantation and usually given as "one-dose-fits-all" together with a calcineurin inhibitor (CNI). Although drug concentrations are frequently monitored, there...
7.
Wind S, Jansen M, Rijsbergen M, van Esdonk M, Ziagkos D, Cheng W, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900424
The authors wish to make the following corrections to this paper [...].
8.
In t Veld A, Grievink H, van der Plas J, Eveleens Maarse B, van Kraaij S, Woutman T, et al.
Immunol Res
. 2023 Feb;
71(4):617-627.
PMID: 36811819
Based on its wide range of immunosuppressive properties, hydroxychloroquine (HCQ) is used for the treatment of several autoimmune diseases. Limited literature is available on the relationship between HCQ concentration and...
9.
In t Veld A, Jansen M, Huisman B, Schoonakker M, de Kam M, Moes D, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145707
Therapeutic drug monitoring (TDM) of calcineurin inhibitors (i.e., tacrolimus and cyclosporin A) is standard of care after solid organ transplantation. Although the incidence of acute rejection has strongly decreased, there...
10.
Wind S, Jansen M, Rijsbergen M, van Esdonk M, Ziagkos D, Cheng W, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326659
Mycosis fungoides (MF) is a subtype of CTCL with a low incidence and high medical need for novel treatments. The objective of this randomized, placebo-controlled, double-blinded, first-in-human study was to...